

Federal Agency For Medicines And Health Products

CERTIFICATE NUMBER: **BE/GMP/2026/003**

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER

^{1, 2}

Part 1

Issued following an inspection in accordance with
Art. 63 of Regulation (EU) 536/2014 as amended

The competent authority of Belgium confirms the following:

The manufacturer: ***Eurofins Amatsigroup***

Manufacturer's alternative name: ***Eurofins Amatsigroup N.V.***

Site address: ***Technologiepark-Zwijnaarde 94, Gent, Oost-Vlaanderen, 9052, Belgium***

Additional details on units inspected: ***Drug Substance unit (unit 14, 19, 21 en 23)***

OMS Organisation Id. / OMS Location Id.: ***ORG-100016462 / LOC-100052554***

Has been inspected under the national inspection programme in connection with manufacturing
authorisation no. ***1750 IMP*** in accordance with Art. 61 of Regulation (EU) No 536/2014.

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted
on ***2026-02-11***, it is considered that it complies with:

- The principles and guidelines of Good Manufacturing Practice laid down in Directive (EU) 2017/1572 and/or Commission Delegated Regulation (EU) 2017/1569, as reflected by the product categories stated in Part 2.³

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. Updates to restrictions or clarifying remarks can be identified through the EudraGMDP website (<http://eudragmdp.ema.europa.eu/>).

This certificate is valid only when presented with all pages and both Parts 1 and 2.

The authenticity of this certificate may be verified in EudraGMDP. If it does not appear, please contact the issuing authority.

¹ The certificate referred to in paragraph Art. 15 of Directive 2001/20/EC is also applicable to importers.

² Guidance on the interpretation of this template can be found in the Interpretation of the Union format for GMP certificate.

³ These requirements fulfil the GMP recommendations of WHO.

Part 2

Human Investigational Medicinal Products	
1 MANUFACTURING OPERATIONS	
1.2	Non-sterile products
	<i>1.2.1 Non-sterile products (processing operations for the following dosage forms)</i> 1.2.1.5 Liquids for external use 1.2.1.6 Liquids for internal use
	<i>1.2.2 Batch certification</i>
1.3	Biological medicinal products (list of product types)
	<i>1.3.1 Biological medicinal products (list of product types)</i> 1.3.1.2 Immunological products 1.3.1.5 Biotechnology products
	<i>1.3.2 Batch Certification (list of product types)</i> 1.3.2.2 Immunological products 1.3.2.5 Biotechnology products
1.4	Other products or manufacturing activity
	<i>1.4.1 Manufacture of</i> 1.4.1.3 Other: Biological active drug substances(en)
1.5	Packaging
	<i>1.5.1 Primary Packaging</i> 1.5.1.5 Liquids for external use 1.5.1.6 Liquids for internal use
1.6	Quality control testing
	<i>1.6.2 Microbiological: non-sterility</i> <i>1.6.3 Chemical/Physical</i> <i>1.6.4 Biological</i>

2026-06-03

Name and signature of the authorised person of the
Competent Authority of Belgium

Confidential
Federal Agency For Medicines And Health Products
Tel: **Confidential**
Fax: **Confidential**